Literature DB >> 16511920

Loss of cortical bone from the metacarpal diaphysis in patients with rheumatoid arthritis: independent effects of systemic inflammation and glucocorticoids.

José F Roldán1, Inmaculada Del Rincón, Agustín Escalante.   

Abstract

OBJECTIVE: To identify factors associated with the loss of cortical diaphyseal bone over time in patients with rheumatoid arthritis (RA).
METHODS: We measured the combined cortical thickness (CCT) of the second metacarpal bone from digitized hand radiographs in an RA cohort. We estimated the rate of loss of CCT, and tested the effect of factors that could accelerate the rate.
RESULTS: We studied 649 patients, who had 2990 hand radiographs. The median interval between the first and last followup radiograph was 2 years (range 0 to 23 yrs). The mean CCT at baseline was 4.04 mm (standard deviation 1.18). CCT loss was greatest during the earliest observation stages, following a square-root function of time at a rate of 0.393 mm/year(1/2) (95% CI 0.360, 0.423). Patients with a mean erythrocyte sedimentation rate (ESR) < 30 mm/h lost CCT at a rate of 0.303 mm/year(1/2) (95% CI 0.247, 0.358); those with a mean ESR > 30 and < or = 60 mm/h lost CCT at 0.395 mm/year(1/2) (95% CI 0.345, 0.446); and those with ESR > 60 mm/h lost CCT at 0.554 mm/year(1/2) (95% CI 0.480, 0.628). Patients who received a cumulative dose of glucocorticoids > or = 11.7 g lost CCT at 0.659 mm/year(1/2) (95% CI 0.577, 0.742), compared to 0.361 mm/year(1/2) (0.323, 0.401) in patients who did not receive glucocorticoids. In a multivariable model, the effect of the ESR and cumulative glucocorticoids was independent of age at RA onset, RA duration, sex, ethnic group, body mass index, presence of rheumatoid nodules, rheumatoid factor, and the HLA-DRB1 shared epitope.
CONCLUSION: Early rapid loss of cortical diaphyseal bone occurs in patients with RA, followed by gradual slowing. Systemic inflammation and glucocorticoids seem to accelerate bone loss independently of other risk factors. Cortical diaphyseal bone may be an important target of the disease process in RA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511920

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 2.  Macrophages and skeletal health.

Authors:  Megan N Michalski; Laurie K McCauley
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

3.  [Comorbidity in rheumatoid arthritis of early onset. Effects on outcome parameters].

Authors:  G Westhoff; C Weber; A Zink
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

4.  Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients?

Authors:  Izabela Korczowska; Anna Olewicz-Gawlik; Jakub Trefler; Paweł Hrycaj; Jan Krzysztof Łacki
Journal:  Clin Rheumatol       Date:  2007-10-02       Impact factor: 2.980

5.  Inflammatory bone loss associated with MFG-E8 deficiency is rescued by teriparatide.

Authors:  Megan N Michalski; Anna L Seydel; Erica M Siismets; Laura E Zweifler; Amy J Koh; Benjamin P Sinder; J Ignacio Aguirre; Kamran Atabai; Hernan Roca; Laurie K McCauley
Journal:  FASEB J       Date:  2018-02-22       Impact factor: 5.191

6.  Time-averaged disease activity of rheumatoid arthritis associated with long-term bone mineral density changes.

Authors:  Chung-Yuan Hsu; Jia-Feng Chen; Yu-Jih Su; Ying-Chou Chen; Han-Ming Lai; Shan-Fu Yu; Hsiao-Ru He; Tien-Tsai Cheng
Journal:  Ther Adv Chronic Dis       Date:  2020-12-23       Impact factor: 5.091

7.  Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss.

Authors:  K Kaur; R Hardy; M M Ahasan; M Eijken; J P van Leeuwen; A Filer; A M Thomas; K Raza; C D Buckley; P M Stewart; E H Rabbitt; M Hewison; M S Cooper
Journal:  Ann Rheum Dis       Date:  2009-06-22       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.